ClinicalTrials.gg
RecruitingNCT04092673ZotatifinUpdated May 21, 2024

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

A Phase 1/2 interventional study of eFT226 and Sotorasib in Solid Tumor, Adult, sponsored by Effector Therapeutics. Recruiting at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-21.

Sponsored by Effector Therapeutics · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Oct 2019; still recruiting 7 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.

Read the detailed description

Part 1 (Dose Escalation): Completed; Recommended Phase 2 Dose (RP2D) and Maximum Tolerated Dose (MTD) identified

Part 1a (Dose Escalation) This cohort will enroll patients with an advanced breast cancer that is refractory or intolerant to SOC therapy.

Part 1b (Dose Escalation) This cohort will enroll patients with an advanced breast cancer that is refractory or intolerant to SOC therapy.

Part 2 (Expansion Cohort) provides defined expansion cohorts to further explore the safety, pharmacology, and clinical activity of eFT226 monotherapy and in various combinations in subjects with previously treated advanced solid tumor malignancies.

02

Conditions studied

  • Solid Tumor, Adult
03

In context

Lead sponsor

Effector Therapeutics is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Criteria:

Parts 1a and 1b (Dose Escalation + Fulvestrant):

  • Patient has histological or cytological confirmation of breast cancer.
  • Patient has disease or locoregionally recurrent disease which is or intolerant to existing therapy(ies) known to provide clinical benefit.
  • Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:

    • Minimum of one for advanced/metastatic disease.
    • Maximum of five prior lines of therapy for advanced/metastatic disease.
    • Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting.
    • Prior treatment has included a CDK4/6 inhibitor.
  • Tumor is ER+ (defined as ER IHC staining > 0%).

Cohort EMNK:

  • Patient has undergone treatment with platinum-based chemotherapy and an /L1 agent, if appropriate.
  • Tumor has a known KRAS-activating mutation; Patients with KRAS G12C mutations are excluded.

Cohort EMBF:

  • Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:

    • Minimum of one prior line of therapy for advanced/metastatic disease.
    • Maximum of five prior lines of therapy for advanced/metastatic disease.
    • Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting, which may include combination therapy (eg, with a CDK4/6 inhibitor).
  • Tumor is ER+ (defined as ER IHC staining > 0%) and has FGFR amplification.

Cohort EMBH:

  • Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:

    • Minimum of one prior line of therapy for advanced/metastatic disease.
    • Minimum of one line of -directed therapy Note: Prior treatment with CDK4/6 inhibitors is permitted.
  • Tumor is ER+ (defined as ER IHC staining > 0%) and HER2+ (defined as HER2 3+ IHC staining or HER2 2+ and FISH+).

Cohort ECNS:

  • Patient has or cytologically confirmed stage IIIB (pleural or pericardial effusion) or stage IV NSCLC.
  • Patient has undergone treatment with platinum-based chemotherapy and an anti-PD-1/L1 agent, if appropriate. Note: Patients who have declined approved therapy(ies) or who per treating physician are not eligible for approved therapy(ies) (eg, due to intolerance) may be eligible following discussion with the Medical Monitor.
  • Tumor has a known G12C KRAS-activating mutation. Note: Patients who have been previously treated with KRAS-specific therapy are excluded.

Cohort ECBF:

  • Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:

    • Minimum of one prior line of therapy for advanced/metastatic disease.
    • Maximum of five prior lines of therapy for advanced/metastatic disease.
    • Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting.
    • Prior treatment has included a CDK4/6 inhibitor.
  • Tumor is ER+ (defined as ER IHC staining > 0%).

Cohort ECBF+A:

  • Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:

    • Minimum of one prior line of therapy for advanced/metastatic disease.
    • Maximum of five prior lines of therapy for advanced/metastatic disease.
    • Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting.
  • Tumor is ER+ (defined as ER IHC staining > 0%) and HER2- (defined as absence of HER2 3+ IHC staining and/or absence of FISH+).

Cohort ECBT:

  • Patient has progressed after treatment with at least one approved anti-HER2 agent and has been administered at least one line of chemotherapy.
  • Tumor is HER2+ (defined as HER2 3+ IHC staining or HER2 2+ and FISH+). Cohorts EMBF, EMBH, ECBF, ECBF+A: There is no limit on the number of lines of prior endocrine therapies.

Cohort ECBF-D1:

  • Patient has metastatic disease or locoregionally recurrent disease which is refractory or intolerant to existing therapy(ies) known to provide clinical benefit.
  • Patient has had prior chemotherapy, endocrine therapy, or other therapy as follows:

    • Minimum of one prior line of therapy for advanced/metastatic disease.
    • Maximum of five prior lines of therapy for advanced/metastatic disease.
    • Recurrence or progression on at least one line of endocrine therapy in the advanced/metastatic disease setting.
    • Prior treatment has included a CDK4/6 inhibitor.
  • Tumor is ER+ (defined as ER IHC staining > 0%).
  • Tumor has amplification of Cyclin D1 as determined by next generation sequencing or in situ hybridization.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Part 1: Sequential escalation (Completed)

    eFT226 administered IV weekly in 21-day cycles; dose escalated in sequential cohorts after subjects enrolled in a given cohort have completed DLT evaluation period.

    Drug: eFT226

  • Experimental
    Part 2: Cohort Expansion, Monotherapy, NSCLC, KRAS (EMNK)

    Cohort EMNK

    Drug: eFT226

  • Experimental
    Part 2: Cohort Expansion, Monotherapy, Breast, FGFR (EMBF)

    Cohort EMBF

    Drug: eFT226

  • Experimental
    Part 2: Cohort Expansion, Monotherapy, Breast, HER2 (EMBH)

    Cohort EMBH

    Drug: eFT226

  • Experimental
    Part 2: Cohort Expansion, Combination, Breast, Fulvestrant (ECBF)

    Cohort ECBF; Combination therapy partner administered per SOC at the approved dose.

    Drug: Fulvestrant

  • Experimental
    Part 2: Cohort Expansion, Combination, NSCLC, Sotorasib (ECNS)

    Cohort ECNS; Combination therapy partner administered per SOC at the approved dose.

    Drug: Sotorasib

  • Experimental
    Part 2: Cohort Expansion, Combination, Breast, Fulvestrant+Abemaciclib (ECBF+A)

    Cohort ECBF+A; Combination therapy partner administered per SOC at the approved dose.

    Drug: Fulvestrant · Drug: Abemaciclib

  • Experimental
    Part 2: Cohort Expansion, Combination, Breast, Trastuzumab (ECBT)

    Cohort ECBT; Combination therapy partner administered per SOC at the approved dose.

    Drug: Trastuzumab

  • Experimental
    Part 1a: Dose Escalation, Combination, Breast

    eFT226 administered IV weekly in 21-day cycles. Fulvestrant will also be given. Dose escalations per protocol.

    Drug: Fulvestrant

  • Experimental
    Part 1b Dose Escalation, Combination, Breast

    eFT226 administered IV every other week in 14-day cycles. Fulvestrant will also be given. Dose escalations per protocol.

    Drug: Fulvestrant

  • Experimental
    Part 2 Cohort Expansion, Combination, Breast, Fulvestrant, Cyclin D1

    ECBF-D1; Combination therapy partner administered per SOC at the approved dose.

    Drug: Fulvestrant

Interventions

  • DrugeFT226

    eFT226 is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics as an anticancer therapy. eFT226 is a potent and selective inhibitor of eIF4A1-mediated translation and selectively regulates the translation of a subset of mRNAs based on sequence specific recognition motifs in their 5'-UTR. eIF4A1 inhibition by eFT226 downregulates expression of receptor tyrosine kinases and KRAS, leading to decreased signaling through the PI3K/AKT and MAPK pathways. Preclinical efficacy testing of eFT226 demonstrates activity across models of solid tumor cancers with amplifications in HER2, FGFR1/2 and mutations in KRAS (including breast, NSCLC and CRC).

    Also known as: Selective translation inhibitor

  • Recommended dosage: 960 mg orally once daily

    Also known as: Lumarkus

  • 500 mg administered intramuscularly on Days 1, 15, 29, and once monthly thereafter

    Also known as: Faslodex

  • Dose in combination with fulvestrant: 150 mg twice daily

    Also known as: Verzenia

  • 600 mg every 3 weeks

    Also known as: Herceptin

06

What researchers measure

Primary outcomes

  1. Parts 1a and 1b: MTD

    determined by occurrence of first cycle DLTs within a 3+3 or 3+3+3 clinical trial design

    Time frame: Through study completion, approximately 12 months

  2. Parts 1a and 1b; incidence of AEs, serious adverse events (SAEs), and DLTs

    according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)

    Time frame: Through study completion, approximately 12 months

  3. Parts 1a and 1b: RP2D

    determined by Incidence and type of DLTs

    Time frame: Through study completion, approximately 12 months

  4. Parts 1a and 1b: RP2D

    determine by Incidence, type, and severity of AEs and SAEs graded as per NCI CTCAE

    Time frame: Through study completion, approximately 12 months

  5. Part 2: Objective Response Rate- Efficacy

    defined as confirmed Complete Response (CR) or Partial Response (PR)

    Time frame: Through study completion, approximately 12 months

  6. Part 2: (Combination Cohorts) Determine MTD

    determined by occurrence of first cycle Dose Limiting Toxicities (DLTs) within the study design

    Time frame: Through study completion, approximately 12 months

  7. Part 2: (Combination Cohorts) Incidence, type, and severity of AEs and SAEs

    via adverse event monitoring

    Time frame: Through study completion, approximately 12 months

  8. Part 2: (Combination Cohorts) Determine RP2D

    determined by incidence and type of DLTs, and incidence, type, and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Through study completion, approximately 12 months

  9. Part 2: Percent change in tumor dimensions of target lesions- Efficacy

    calculated by the percentage change from baseline in the sum of the LD of target lesions

    Time frame: Through study completion, approximately 12 months

  10. Part 2: Time to Response (TTR)- Efficacy

    defined as the interval from the start of study therapy to the first documentation of an objective response

    Time frame: Through study completion, approximately 12 months

  11. Part 2: Duration of Response (DOR)- Efficacy

    defined as the interval from the first documentation of objective response to the earlier of the first documentation of disease progression or death from any cause

    Time frame: Through study completion, approximately 12 months

Secondary outcomes

  1. Parts 1a and 1b: Objective response

    determined by confirmed CR or PR

    Time frame: Through study completion, approximately 12 months

  2. Parts 1a and 1b: Percent change in tumor dimensions of target lesions

    calculated by the percentage change from baseline in the sum of the LD of target lesions

    Time frame: Through study completion, approximately 12 months

  3. Parts 1a and 1b: TTR

    defined as the interval from the start of study therapy to the first documentation of an objective response

    Time frame: Through study completion, approximately 12 months

  4. Parts 1a and 1b: DOR

    defined as the interval from the first documentation of objective response to the earlier of the first documentation of disease progression or death from any cause

    Time frame: Through study completion, approximately 12 months

  5. Parts 1a and 1b: PFS

    defined as the interval from the start of study therapy to the earlier of the first documentation of disease progression or death from any cause

    Time frame: Through study completion, approximately 12 months

  6. Part 2: (Monotherapy and Combination Cohorts) Incidence and severity of AEs, SAEs, and additional safety parameters

    via adverse event monitoring

    Time frame: Through study completion, approximately 12 months

  7. Part 2: Progression Free Survival

    defined as the interval from the start of study therapy to the earlier of the first documentation of disease progression or death from any cause

    Time frame: Through study completion, approximately 12 months

  8. Evaluate plasma Pharmacokinetic (PK) parameters of eFT226

    including area under the plasma concentration-time curve

    Time frame: Through study completion, approximately 12 months

  9. Evaluate plasma Pharmacokinetic (PK) parameters of eFT226

    including maximum concentration

    Time frame: Through study completion, approximately 12 months

  10. Evaluate plasma Pharmacokinetic (PK) parameters of eFT226

    including terminal phase rate constant

    Time frame: Through study completion, approximately 12 months

  11. Evaluate plasma Pharmacokinetic (PK) parameters of eFT226

    including estimated steady-state volume of distribution \[Vss\]

    Time frame: Through study completion, approximately 12 months

  12. Evaluate plasma Pharmacokinetic (PK) parameters of eFT226

    including half-life (t½)

    Time frame: Through study completion, approximately 12 months

  13. Evaluate plasma Pharmacokinetic (PK) parameters of eFT226

    including total body clearance

    Time frame: Through study completion, approximately 12 months

  14. Evaluate plasma Pharmacokinetic (PK) parameters of eFT226including terminal state volume of distribution

    including terminal state volume of distribution

    Time frame: Through study completion, approximately 12 months

  15. Evaluate plasma Pharmacokinetic (PK) parameters of eFT226 including terminal phase rate constant

    including terminal phase rate constant

    Time frame: Through study completion, approximately 12 months

07

Study locations

10 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — There is not a plan to make IPD available

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2019 (actual). Primary completion is estimated for Dec 2024, 62 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2019
First posted
Sep 17, 2019
StartActual
Oct 25, 2019
Primary completionEst.
Dec 31, 2024
CompletionEst.
Mar 31, 2025
Last update
May 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04092673
Lead sponsor
Effector Therapeutics
Responsible party
Sponsor
First posted
Sep 17, 2019
Start date
Oct 25, 2019
Primary completion
Dec 31, 2024 (estimated)
Completion
Mar 31, 2025 (estimated)
Last update
May 21, 2024

Study contacts

Mark Densel
Contact
clinicaltrials@effector.com
858-925-8215
Douglas Warner, MD
study director · EFFECTOR Therapeutics, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zotatifin · Sotorasib

Start the discussion